Alzheimer Disease Clinical Trials in Indianapolis, Indiana

5 studies are recruiting for alzheimer disease in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Care Access - South Indianapolis, Indianapolis, Indiana

   Locations

   59 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

2. Trial-Ready Cohort-Down Syndrome (TRC-DS)

   The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-D…

   Stage

   Not phased

   Ages

   25 to 55

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   22 in total

   Run by

   University of Southern California

   See if you can join NCT04165109 on ClinicalTrials.gov

3. Late Onset Alzheimer's Disease

   The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to…

   Stage

   Not phased

   Ages

   55 and older

   Site

   NCRAD at Indiana University, Indianapolis, Indiana

   Locations

   12 in total

   Run by

   Columbia University

   See if you can join NCT05010603 on ClinicalTrials.gov

4. Nicotinic Acid for the Treatment of Alzheimer's Disease

   Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid. One dose of 500 mg nic…

   Stage

   Phase 1

   Ages

   60 to 85

   Site

   IU Health Neuroscience Center, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT06582706 on ClinicalTrials.gov

5. I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

   This study is a randomized, controlled trial (RCT) to evaluate the effect of Brain CareNotes (a mobile health application) on the burden experienced by unpaid caregivers of patients with dementia and on the behavioral and psychological symptoms of dementia (BPSD) displayed by care recipients. Over …

   Stage

   Not phased

   Ages

   18 and older

   Site

   IU Health, Indianapolis, Indiana

   Locations

   2 in total

   Run by

   Indiana University

   See if you can join NCT05733520 on ClinicalTrials.gov